key: cord-1055193-i1eaddus
authors: Rivas-Fuentes, Selma; Valdés, Víctor Julián; Espinosa, Blanca; Gorocica-Rosete, Patricia; Salgado-Aguayo, Alfonso
title: Could SARS-CoV-2 blocking of ACE2 in endothelial cells result in upregulation of CX3CL1, promoting thrombosis in COVID-19 patients?
date: 2021-03-25
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2021.110570
sha: 17d0a7c7b851811b6f5c38024b57d2158b914492
doc_id: 1055193
cord_uid: i1eaddus

SARS-CoV-2 is the causal agent of COVID-19 disease. Currently, infection with SARS-CoV-2 has been the cause of death of over 2.5 million people globally, and there is still no effective curative treatment. Clinically, the severe symptoms caused by COVID-19, in addition to pneumonia, are associated with the development of hyperinflammatory syndrome and thrombosis. It is urgent to expand our understanding of the molecular mechanisms involved in the pathophysiology of COVID-19. This article discusses the potential role that the chemokine CX3CL1 could have in the development of COVID-19-associated thrombosis. CX3CL1 is abundantly expressed by activated endothelium and is an important regulator of many aspects of endothelial function and dysfunction, including thrombosis. The generation of hypotheses about molecules that could be relevant in well-defined aspects of the pathophysiology of COVID-19 encourages the development of basic and clinical studies, that could help find effective and much needed treatments.

52 Lung tissue from deceased COVID-19 patients presents diffuse alveolar damage, infiltration of T 53 cells in the perivascular area, severe endothelial damage, thrombosis, and generalized 54 microangiopathy in the pulmonary vessels [2] . In addition to the damage at the lung level, SARS-55 CoV-2 is able to produce various systemic effects. Clinically, severe COVID-19 cases are frequently 56 associated with the development of serious cardiovascular conditions such as arterial and venous 57 thromboembolism, which significantly increase the relative risk of death in these patients [3, 4] . In 58 this regard, it has been reported that chronic anticoagulant therapy and prophylactic treatment with 59 sodium heparin have been effective in reducing the relative risk of death from COVID-19 [5, 6]. 60 Studying the underlying mechanisms associated with injury and dysfunction of vascular endothelium 61 associated with severe COVID-19 could help find more effective therapeutic options for the disease, 62 and aid in reducing its mortality.

116 Although the biological consequences of negative regulation of ACE2 expression, or a decrease in its 117 activity in endothelial cells, would have severe thrombogenic effects, chemokine CX3CL1 could 118 contribute to perpetuating the thrombotic loop as discussed below. A direct indication that CX3CL1 119 expression might be increased by SARS-CoV-2 infection is found in mice genetically deficient in 120 ACE2 that exhibit increased CX3CL1 expression, especially when hypertrophy and myocardial 121 damage are induced through chronic cardiac administration of Ang-II [22] . Although the molecular 122 mechanism responsible for CX3CL1 upregulation upon ACE2 ablation should be investigated, the 123 link between RAS and this chemokine in vivo is clear.

124 The initial overexpression of CX3CL1 could favor the recruitment of CX3CR1 + immune cells, such 125 as monocytes [29] and cytotoxic T cells, which could produce an inflammatory environment, as has 126 been described in atherosclerosis [30] , and rheumatoid arthritis [31] . In addition, studies carried out 169 170 Consequences of the hypothesis 171 Although more evidence should be collected regarding the upregulation of CX3CL1 in endothelial 172 cells as well as its levels in the plasma of COVID-19 patients, different experimental studies and 173 direct clinical evidence may suggest that the pro-thrombotic cytokine CX3CL1 could be increased 174 and play a role in the pathophysiology of COVID-19. Increased levels of CX3CL1 have been 175 described in cardiovascular disorders, and a recent report found that this chemokine is increased in 176 patients with COVID-19, especially in patients with the severe manifestation of the disease. Indirect 177 studies suggest potential mechanisms by which CX3CL1 could promote vascular damage and 178 thrombosis. Reduction of ACE2 abundance in the cell membrane induced by the spike-mediated 179 endocytosis may not only contribute to aggravate serious cardiovascular conditions such as arterial 180 and venous thromboembolism, but also induce CX3CL1 upregulation in the endothelium, contributing 181 to a pro-thrombotic environment and immune cell recruitment contributing to the harmful cycle 182 associated with severe COVID-19 and its lethality. 

Hyperinflammation in COVID-19 patients is characterized by elevated peripheral levels of the 64 cytokine IL-6. This cytokine also confers a pro-thrombotic environment by inducing the expression 65 of fibrinogen, the precursor of fibrin

Another molecule that 68 could be associated with thrombosis secondary to COVID-19 is the chemokine CX3CL1, which, as 69 will be discussed below, could be positively regulated in the endothelium during SARS-CoV-2 70 infection

The chemokine CX3CL1, also known as fractalkine (FKN), is abundantly expressed in endothelial 72 cells after activation with pro-inflammatory cytokines such as TNF-α and IL-1β

CX3CL1 is cleaved by the inducible ADAM17 metalloprotease in response to 77 inflammatory stimulus such as atherosclerosis, diabetes and post-transplant vasculopathy [14]. As 78 discussed in the Evaluation of Hypothesis section, CX3CL1 could be up-regulated in the endothelium 79 during SARS-CoV-2 infection

Angiotensin Converting Enzyme 2 (ACE2) mediates SARS-CoV-2 internalization 81 through interaction with the coronavirus spike protein (S) [15]. Indeed, human recombinant soluble 82 ACE2 has been used to inhibit SARS-CoV-2 infection of endothelial cells

In an experimental model of induced thrombosis in vena cava, 87 in spontaneously hypertensive rats it was demonstrated that a low activity of ACE2 is a prothrombotic 88 factor [20

CoV-2 mediated 90 downregulation of ACE2 could cause the accumulation of angiotensin II, which ultimately diminishes 91 the capacity to counteract RAS activation contributing to the pathology of COVID-19

A potential pathophysiological mechanism of SARS-CoV-2 infection in endothelial cells could be 96 the blocking or neutralization of the natural function of the ACE2 receptor after endocytosis of viral 97 particles. This condition would lead to the overexpression of CX3CL1, which would promote 98 endothelial damage due to the excessive recruitment of immune cells, and have a pro-thrombotic 99 effect derived from platelet activation

At the cell membrane, SARS-CoV-2 spike protein binding to ACE2 triggers the receptor-104 mediated endocytosis of viral particles after activation by TMPRSS2, a cellular serine protease. It has 105 been proposed that sequestration of ACE2 in acidic endosomes depletes ACE2 from plasma 106 membrane

CoV-2 negatively regulates the expression of ACE2; however, this has been demonstrated in other 108 coronaviruses that use ACE2 as an entry pathway. For example

CoV dramatically reduced by shedding the expression of ACE2 from 24 hours post-infection [25], 110 and depletion of ACE2 has also been documented in lung tissue of animals infected with SARS-CoV

Furthermore, the human coronavirus NL63 has been reported to negatively regulate the 112 expression of the ACE2 protein during its replication

have proposed as 113 a hypothesis that the entry of SARS-CoV-2 virus into the endothelial cell downregulates the 114 expression of the ACE2 receptor, causing an imbalance in the RAS which leads to endothelial damage 115 and activation of the prothrombotic cascade in COVID-19 patients

127 in rats indicate that the increase in the levels of CX3CL1 could have a pro-thrombotic effect

Lung tissue of rats subjected to the acute pulmonary thromboembolism model shows increased levels 129 of CX3CL1 mRNA, and other pro-inflammatory molecules such as TNF-α and IL-1β, however, the 130 mechanisms of these increases remain unknown. Interestingly, anticoagulation treatment with aspirin 131 was found to decrease CX3CL1 mRNA levels, in addition to controlling pulmonary arterial pressure 132 and damage caused by pulmonary embolism [32]. These findings suggest that CX3CL1 133 overexpression accompanies the damage caused by pulmonary thromboembolism. CX3CL1 could 134 promote thrombosis through platelet activation. It has been shown that when platelets are stimulated 135 with CX3CL1 they increase the expression of P-selectin, adhesion to various matrices such as 136 collagen

COVID-19 patients, treatment with heparin has had favorable results in preventing thrombosis

Evidence from in vitro studies indicates that, in human endothelial cells, the expression of CX3CL1 139 might also be decreased with heparin treatment, e.g. in IFN-γ stimulated human umbilical cord 140 endothelial cells, treatment with heparin (4mg/ml) resulted in CX3CL1 downregulation at the 141 transcriptional and protein levels

during convalescence from COVID-19 disease, mainly in hospitalized patients, there is a 144 decrease in blood flow due to the lack of mobility

This 152 upregulation seems to be specific as infection with Influenza A or other coronaviruses such as SARS-153 CoV or MERS did not show a significant change in CX3CL1 expression. In vivo data correlating 154 CX3CL1 upregulation and SARS-CoV-2 infection is currently missing; it will be especially relevant 155 to characterize transcriptional changes upon infection of endothelial cells where expression of 156 CX3CL1 is relevant. However, as mentioned early, ACE2 deficiency triggers an increase in the 157 expression of CX3CL1 in mice [22] and coronavirus spike protein induces downregulation of ACE2 158 in the cell membrane

CoV-2 infection and CX3CL1 upregulation in endothelial cells

On the other hand, a small clinical study evaluated the plasma levels of a panel of adhesion molecules 161 in 39 patients with COVID-19; measured molecules included intercellular adhesion molecule (ICAM-162 1), vascular cell adhesion molecule-1 (VCAM)

The samples were grouped according to illness severity: 9 samples from patients with mild symptoms 164 and 30 samples from patients with severe symptoms were analyzed. The authors found a global 165 increase in plasma levels of adhesion molecules in patients with severe COVID-19, compared to 166 patients with mild symptoms or control individuals. In the case of CX3CL1, patients with severe 167 symptoms presented a 2.1-fold increase in this chemokine in relation to patients with mild symptoms

Comorbidity and its impact on 195 1590 patients with COVID-19 in China: a nationwide analysis

Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic 201 Therapy, and Follow-Up: JACC State-of-the-Art Review

Incidence of 204 thrombotic complications in critically ill ICU patients with COVID-19

Thromboembolic 207 risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action

Anticoagulant treatment is associated with 210 decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Characterization of the IL-6 responsive elements in the 213 gamma fibrinogen gene promoter

Clinical criteria for COVID-215 19-associated hyperinflammatory syndrome: a cohort study

Regulation of CX3CL1/fractalkine expression in endothelial 217 cells

Tumor necrosis factor-alpha induces 219 fractalkine expression preferentially in arterial endothelial cells and mithramycin A 220 suppresses TNF-alpha-induced fractalkine expression

A new class of membrane-222 bound chemokine with a CX3C motif

Fractalkine 224 promotes platelet activation and vascular dysfunction in congestive heart failure

Modulation of platelet and monocyte function by the 227 chemokine fractalkine (CX3 CL1) in cardiovascular disease

Characterization of fractalkine (CX3CL1) and CX3CR1 in 230 human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant 231 vascular disease

Receptor Recognition by the Novel Coronavirus 233 from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus

CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2. 237 Cell

System Inhibitors in Patients with Covid-19

Interaction of SARS-CoV-2 and Other Coronavirus With 242

Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. 243 Hypertension

SARS-CoV-2 pandemic and research gaps

Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy

ACE2 activation 248 promotes antithrombotic activity

Genetic Ace2 250 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout 251 mouse

Loss of angiotensin-converting 253 enzyme 2 exacerbates myocardial injury via activation of the CTGF-fractalkine signaling 254 pathway

The spike protein of SARS-CoV--a target for 256 vaccine and therapeutic development

SARS-CoV-2 receptor ACE2-dependent 258 implications on the cardiovascular system: From basic science to clinical implications

Differential 261 downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome 262 coronavirus and human coronavirus NL63

A crucial role of angiotensin converting 264 enzyme 2 (ACE2) in SARS coronavirus-induced lung injury

Replication-dependent 266 downregulation of cellular angiotensin-converting enzyme 2 protein expression by human 267 coronavirus NL63

SARS-CoV-2 cell 269 entry receptor ACE2 mediated endothelial dysfunction leads to vascular thrombosis in 270 COVID-19 patients

Fractalkine induces angiogenic potential 272 in CX3CR1-expressing monocytes

Fractalkine is 274 expressed in early and advanced atherosclerotic lesions and supports monocyte 275 recruitment via CX3CR1

Migration of CX3CR1-277 positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of 278 patients with rheumatoid arthritis

CX3CL1/CX3CR1 signaling pathway in acute pulmonary embolism

Novel role of 283 the membrane-bound chemokine fractalkine in platelet activation and adhesion

viral particle binding to the ACE2 receptor on the cell membrane of endothelial 310 cells, induces its internalization and intracellular degradation. The decrease in ACE2 function 311 increases the expression of CX3CL1, favoring the recruitment of CX3CR1 + cells, causing an increase 312 in local inflammatory mediators and vascular damage due to immune cells with cytotoxic or 313 inflammatory activity. Vascular damage could also lead to platelet activation and thrombosis by 314 mechanisms dependent on or independent of CX3CL1. Additionally, during hospitalization and/or 315 convalescence